Analysts Set Hologic, Inc. (NASDAQ:HOLX) Price Target at $87.60

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $87.60.

HOLX has been the subject of several recent research reports. Argus boosted their target price on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. JPMorgan Chase & Co. raised their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, July 30th.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

Institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new position in shares of Hologic during the 4th quarter valued at about $950,000. Cerity Partners LLC purchased a new stake in shares of Hologic in the 4th quarter valued at approximately $390,000. Louisiana State Employees Retirement System acquired a new stake in shares of Hologic during the 4th quarter worth approximately $1,057,000. Mackenzie Financial Corp raised its position in shares of Hologic by 17.3% during the 4th quarter. Mackenzie Financial Corp now owns 76,722 shares of the medical equipment provider’s stock valued at $5,482,000 after buying an additional 11,308 shares during the period. Finally, Federated Hermes Inc. raised its position in shares of Hologic by 16.9% during the 4th quarter. Federated Hermes Inc. now owns 9,355 shares of the medical equipment provider’s stock valued at $668,000 after buying an additional 1,355 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.2 %

Hologic stock opened at $80.25 on Monday. The business’s 50-day simple moving average is $77.58 and its two-hundred day simple moving average is $76.07. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.29 and a current ratio of 3.99. The company has a market cap of $18.73 billion, a PE ratio of 40.94, a PEG ratio of 2.64 and a beta of 0.99. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company earned $0.93 EPS. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. Equities analysts anticipate that Hologic will post 4.08 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.